Skip to main content

Table 1 Pharmacokinetics of 213Bi-DOTATATE at 10, 30, 60 and 120 min post injection (p.i.) in H69 tumour-bearing animals, expressed in mean %IA/g ± SD, n = 7

From: Influence of tumour size on the efficacy of targeted alpha therapy with 213Bi-[DOTA0,Tyr3]-octreotate

Uptake (%IA/g)

10 min p.i.

30 min p.i.

60 min p.i.

120 min p.i.

Tumour

7.5 ± 2.2

9.8 ± 2.4

9.8 ± 2.3

6.8 ± 3.2

Muscle

2.1 ± 0.8

1.1 ± 0.2

1.0 ± 1.4

0.5 ± 0.4

Kidney

44.0 ± 9.6

28.5 ± 3.7

26.2 ± 2.6

25.0 ± 3.8

Pancreas

3.2 ± 0.3

2.8 ± 0.3

1.8 ± 0.2

1.4 ± 0.2

Liver

2.1 ± 0.8

0.9 ± 0.09

0.4 ± 0.06

0.3 ± 0.05

Blood

8.1 ± 1.8

2.3 ± 1.1

0.6 ± 0.2

0.1 ± 0.06

Spleen

2.3 ± 0.6

1.0 ± 0.09

0.4 ± 0.07

0.2 ± 0.07

Adrenal

3.6 ± 1.2

2.0 ± 0.6

0.9 ± 0.4

0.7 ± 0.4

Femur

2.8 ± 0.4

1.5 ± 0.4

1.0 ± 0.5

0.4 ± 0.4

  1. %IA/g = mean percentage of total injected radioactivity per gram tissue